Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 2/20 | 0.31 |
| ▸ | REN | P00797 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23513610 | 0.86 | MAPT (0.38) | HRH3KCNH2CYP2D6MAPTTDP1 | |
| SCHEMBL9963221 | 0.86 | MAPT (0.38) | HRH3KCNH2CYP2D6MAPTTDP1 | |
| SCHEMBL12259250 | 0.75 | MAPT (0.44) | ALDH1A1HRH3MAPTNOTUM | |
| SCHEMBL23513695 | 0.75 | ALDH1A1 (0.40) | ALDH1A1TDP1 | |
| SCHEMBL7882719 | 0.75 | MAPT (0.44) | ALDH1A1HRH3MAPTNOTUM | |
| SCHEMBL12258806 | 0.75 | MAPT (0.44) | ALDH1A1HRH3MAPTNOTUM | |
| SCHEMBL14558079 | 0.73 | ALDH1A1 (0.36) | ALDH1A1HRH3KCNH2CYP2D6MAPT | |
| SCHEMBL22719696 | 0.71 | TFPI2 (0.34) | TDP1NOTUM | |
| SCHEMBL21037187 | 0.70 | S1PR5 (0.35) | ALDH1A1HRH3KCNH2CYP2D6MAPT | |
| SCHEMBL26205508 | 0.70 | HRH3 (0.36) | ALDH1A1HRH3KCNH2CYP2D6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210179580-A1 | PYRIMIDINE DERIVATIVES AS INHIBITORS OF PD1/PD-L1 ACTIVATION | Jubilant Prodel LLC | 2021-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179580-A1 | PYRIMIDINE DERIVATIVES AS INHIBITORS OF PD1/PD-L1 ACTIVATION | PDCD1, CD274, PDCD1LG2 | ALDH1A1 37/4885HRH3 2463/4885KCNH2 3721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.